Final Program Introduction of CVRFAstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cardiovascular, cancer, gastrointestinal, infection.
Booth No. B37
| Lunchtime Activities | |
| Evidence Based Practice: Clinical Implementation of Newly Updated ESC Guideline & Real-World East Asian Data of P2Y12 Inhibitors | |
| Organized by CVRF and Supported by Educational Grant from AstraZeneca Korea | |
|
Monday, April 30 12:45 PM - 1:45 PM Room 201, Level 2 |
|
| Moderator(s): Myeong-Ki Hong, Seung-Ho Hur | |
| Panelist(s): Sung Gyun Ahn, Jung Ho Heo, Chan Joon Kim, Weon Kim, Jin Bae Lee, Keun-Ho Park, Wook Bum Pyun | |
| 12:45 PM | Opening Remark
Speaker : Seung-Ho Hur
|
| 12:50 PM | Proven Secondary Prevention Effect of Ticagrelor from 2017 ESC DAPT Guideline and PEGASUS TIMI-54
Lecturer : Joo-Yong Hahn
|
| 1:00 PM | Using Pattern and Clinical Impact of New Antiplatelet Agents on 1-Year Outcome After AMI: Korean Health Insurance Review and Assessment Data
Lecturer : Dong-Ho Shin
|
| 1:10 PM | The Efficacy and Safety of Ticagrelor Versus Clopidogrel in Acute Myocardial Infarction in Taiwan
Lecturer : Yi-Heng Li
|
| 1:20 PM | Panel Discussion |
| 1:40 PM | Closing Remark
Speaker : Myeong-Ki Hong
|
